Navigation Links
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Date:1/7/2008

bcast. To access the live webcast, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's corporate website at http://investor.pharmasset.com/events.cfm.

Please connect to the company's website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary to listen to the webcast. The archived replay of the webcast will be available on the Pharmasset website for two weeks following the conference call.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 demonstrated potent, dose-dependent antiviral activity across four patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once- daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- An international roster of experts on malignant pleural mesothelioma ... Santa Monica, Calif. , to discuss their latest ... rare form of cancer that results from exposure to ... the chest. Hosted by UCLA and the ... International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma ...
(Date:5/24/2013)... Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a leading provider ... Robert Grieve , the Company,s chairman and ... executive vice president and chief financial officer, will present at ... May 30, 2013 in New York City ... Company,s presentation is scheduled to begin at 1:30 p.m. EDT. ...
(Date:5/24/2013)... BEIJING , May 24, 2013 China ... "Company"), a leading fully integrated plasma-based biopharmaceutical company in ... Company has recently learned from a public announcement issued ... a public company listed on Shenzhen Stock Exchange, that ... Chan ("Ms. Chan"), one of the shareholders ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4
... Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: ... focusing on the development, manufacturing, marketing and selling of ... it plans to release its fourth quarter and full ... March 25, 2011. Tongjitang,s management team will ...
... MADISON, N.J., March 21, 2011 Quest Diagnostics ... provider of diagnostic testing, information and services, announced ... aggregate principal amount of four series of senior ... shelf registration statement filed with the Securities and ...
Cached Medicine Technology:Tongjitang Chinese Medicines Company to Announce Fourth Quarter and Full Year 2010 Financial Results 2Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering 2
(Date:5/24/2013)... new neurons in the hippocampus - a brain region ... could cause forgetting of old memories by causing a ... and Sheena Josselyn, both from the Hospital for Sick ... positive effect of clearing old memories, reducing interference and ... were presented at the 2013 Canadian Neuroscience Meeting, the ...
(Date:5/24/2013)... New York, NY (PRWEB) May 24, 2013 ... has granted Cellular Dynamics International (CDI) exclusive license rights ... cell therapy and regenerative medicine applications. These cells are ... of the heart, including cardiomyocytes, endothelial cells, and vascular ... a potential therapeutic for damaged heart tissue. , The ...
(Date:5/24/2013)... On May 16, students, family members, and ... American University of Antigua (AUA) College of Medicine ... was the largest graduating class to date. The ceremony ... Vice President for Enrollment Management and Chief Operating Officer, ... Dean of Students and Professor and Chair – Physiology, ...
(Date:5/24/2013)... 2013 The creative flair and design ... University (PolyU)'s Institute of Textiles and Clothing (ITC) have ... Fashion Show held on 22 May at The Mira ... of ITC design students, various knitwear producers and yarn ... collections of four outfits from 20 graduating students majoring ...
(Date:5/24/2013)... THURSDAY, May 23 (HealthDay News) -- Type 2 diabetes ... of serious complications seen just a few years after ... latest results, it seems like type 2 is progressing ... vice president of medical affairs and community information for ... it appears to be at a more significant rate ...
Breaking Medicine News(10 mins):Health News:New neuron formation could increase capacity for new learning, at the expense of old memories 2Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 2Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 3Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 4Health News:AUA Celebrates Seventh Annual Commencement Ceremony 2Health News:PolyU Stages Knitwear Fashion Show 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 3
... Tragedy: The mass shooting in Tucson that ... Congresswoman Gabrielle Giffords, brought significant attention to ... mental, emotional and behavioral disorders (MEBs) and substance abuse. ... be answered by a panel of experts, including Ron ...
... promising cancer treatment drug can restore function of a heart ... UT Southwestern Medical Center have found. The drug, a ... ongoing clinical trials, has been shown to reverse the harmful ... is a natural process by which cells eat their own ...
... enzyme associated with extensive antibiotic resistance called New Delhi ... worldwide, has been found in two people in the ... states a case report in CMAJ ( ... http://www.cmaj.ca/embargo/cmaj110477.pdf . The report outlines challenges and approaches to ...
... May 29 (HealthDay News) -- Attacks by North American black ... rising as the human population of the United States and ... in the Journal of Wildlife Management , also dispels ... mothers with cubs to protect. Researchers reveal that lone male ...
... -- Native American children in the United States and Canada ... other kids, according to a new policy statement from a ... oral health of those patients. A survey of 2,633 ... the United States, Alaska and Canada found that 68 percent ...
... symptoms is distressing for both patient and doctor and ... five patients have symptoms that remain unexplained by conventional ... NHS of managing the treatment of a patient with ... patient with a diagnosis. A research team ...
Cached Medicine News:Health News:Tucson tragedy; college athletes and drinking; depression in adolescents; and yoga and drug use 2Health News:Drug can reverse overgrown hearts to help prevent heart failure, UT Southwestern researchers find 2Health News:New Delhi metallo-beta-lactamase-1 enzyme acquired in Canada 2Health News:Fatal Black Bear Attacks Rare But Rising 2Health News:Native American Children Have More Tooth Decay 2Health News:Acupuncture of benefit to those with unexplained symptoms 2Health News:Acupuncture of benefit to those with unexplained symptoms 3
... early 1990s, the "Reversed" shoulder prosthesis has ... great success. More recently, an ever-growing number ... begun to champion this prosthesis and the ... This reversed technology is the result of ...
... spectrofluorometer is the ... among the FLUORAT®-02 ... intended for scientific ... and for operation ...
... The Gemini XPS spectrofluorometer ... measurements as required by ... assays. Cellular and molecular ... drug screening, and SNP ...
The FluoroMax-3 is the entry level spectrofluorometer from Spex®, yet offers features not found in most of the top models of the competition....
Medicine Products: